News
CYCC
2.110
+7.65%
0.150
Cyclacel Pharma: General form for registration of securities under the Securities Act of 1933
Press release · 3d ago
Weekly Report: what happened at CYCC last week (0318-0322)?
Weekly Report · 4d ago
CYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023
Cyclacel Pharmaceuticals reported earnings per share of -$6.23. The company reported revenue of $31,000. This was below the analyst estimate for EPS of $5.89. The stock was down 2.7% after the market closed.
Investorplace · 03/20 00:53
Cyclacel Pharmaceuticals GAAP EPS of -$6.23 misses by $0.34
Cyclacel Pharmaceuticals' Q4 GAAP EPS of -$6.23 misses by $0.34. The company expects to have $6.3 million in cash and cash equivalents as of December 31, 2024. The Company expects to fund its planned programs through 2024.
Seeking Alpha · 03/19 20:15
*Cyclacel Pharmaceuticals: On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H24 >CYCC
Dow Jones · 03/19 20:10
*Cyclacel Pharmaceuticals 4Q Rev $31,000 >CYCC
Dow Jones · 03/19 20:09
*Cyclacel Pharmaceuticals 4Q EPS 0c >CYCC
Dow Jones · 03/19 20:09
Cyclacel Pharmaceuticals Q4 EPS $(6.23) Misses $(5.89) Estimate, Sales $31.00K
Benzinga · 03/19 20:06
Press Release: Cyclacel Pharmaceuticals Reports -2-
Cyclacel Pharmaceuticals, Inc. Has reported results for the three and 12 months ended December 31, 2017. The company has a net loss of $27.7 million. The company reported revenues of $7.2 million in the three months ended Dec. 31, 2016.
Dow Jones · 03/19 20:05
Earnings Scheduled For March 19, 2024
Tencent Music Enter Gr is projected to report quarterly earnings at $0.14 per share on revenue of $931.97 million. Companies Reporting Before The Bell include HUYA, Caleres and XPeng. Mitek Systems is likely to report earnings for its fourth quarter.
Benzinga · 03/19 10:06
Notable earnings after Tuesday's close
Major earnings expected after the bell on Tuesday include: TKC, CYCC, PGEN, RLMD, HQY, CRVS, ZTO, HROW, TSHA. Other major earnings slated for release after Tuesday's close include: CYCC and PGEN.
Seeking Alpha · 03/18 21:35
Earnings Outlook For Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is set to give its latest quarterly earnings report on Tuesday, 2024-03-19. Analysts estimate the company will report an earnings per share of $-5.89. Last quarter the company missed EPS by $1.95 and shares are down 73.11% over the last 52-week period.
Benzinga · 03/18 15:00
Weekly Report: what happened at CYCC last week (0311-0315)?
Weekly Report · 03/18 10:53
Earnings week ahead: FedEx, Nike, XPeng, Tencent, General Mills and more
Earnings week of March 18 to 22 will feature major quarterly updates from FedEx, XPeng, Tencent, General Mills and more. The week will also feature important announcements from Nike, Lululemon Athletica and Chewy. Technology companies are also in focus with earnings results from Micron, Accenture and others.
Seeking Alpha · 03/17 12:20
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
Cyclacel Pharmaceuticals, Inc. Will announce fourth quarter and full year 2023 financial results on March 19, 2024. The company is a biopharmaceutical company developing innovative medicines based on cancer cell biology. The Company will host a conference call on the same day.
Barchart · 03/13 15:05
Weekly Report: what happened at CYCC last week (0304-0308)?
Weekly Report · 03/11 10:50
Cyclacel Pharmaceuticals receives $2.9M R&D tax credit
Cyclacel Pharmaceuticals receives $2.9M R&D tax credit from the UK government. The company expects to receive an additional $0.8M in the future. The tax credit is based on R&d costs incurred in the year ended Dec. 31, 2023.
Seeking Alpha · 03/06 14:41
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
Cyclacel Pharmaceuticals, Inc. Received £2.3 million as a research & development tax credit from HMRC. The tax credit is based on R&D costs incurred in the year ended December 31, 2023. The company is developing innovative medicines based on cancer cell biology.
Barchart · 03/06 08:15
Weekly Report: what happened at CYCC last week (0226-0301)?
Weekly Report · 03/04 10:53
Cyclacel Pharmaceuticals Inc <CYCC.OQ> expected to post a loss of $5.89 a share - Earnings Preview
Cyclacel Pharmaceuticals Inc expected to post a loss of $5.89 a share - Earnings Preview. The company is expected to show change in quarterly revenue when it reports results on March 4. Average analyst rating on the shares is "buy"
Reuters · 03/01 11:06
More
Webull provides a variety of real-time CYCC stock news. You can receive the latest news about Cyclacel Pharma through multiple platforms. This information may help you make smarter investment decisions.
About CYCC
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.